Proton Pump Inhibitors

Drug Safety Updates

April 2012 : Prolonged use of proton pump inhibitors (PPIs) has been associated with hypomagnesaemia - consider checking magnesium levels before starting treatment and repeat measurements periodically during treatment.

 April 2012: Long-term use of PPIs has also been linked to fracture. 

 September 2015: Proton pump inhibitors are associated with infrequent cases of subacute cutaneous lupus erythematosus. 

NICE Guidance

CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, September 2014 (updated October 2019)

CG141: Acute upper gastrointestinal bleeding in over 16s: management, June 2012 (updated August 2016)

Local Guidance

See here for K&M ICB position statements on the use of omeprazole oral suspension for adults or paediatrics in primary care.

GORD patients with simple reflux should be encouraged to make healthy lifestyle changes eg weight loss, avoid large fatty meals and raise the head of the bed at night. Patients with GORD should be given full dose PPI for 2 months . If symptoms recur and in complicated reflux long term maintenance should be considered.

PPIs should be prescribed for appropriate indications at the lowest effective dose for the shortest period; the need for long-term treatment should be reviewed periodically.

Intravenous PPI is used for patients with confirmed upper GI bleeding and those with endoscopic evidence of recurrent haemorrhage. PPIs should not be used prior to diagnosis by endoscopy in patients with upper GI bleeding.

OTC pack sizes available may be different to the pack sizes listed here.

Choices for dispersible tablets:

Omeprazole dispersible tablets are the first choice PPI for children (>1 year and >10kg) who cannot swallow the capsules in both hospital and community.

For adult patients with swallowing difficulty the first choice PPI is omeprazole dispersible for community and lansoprazole dispersible for hospital.

In some instances, it is more appropriate for patients to remain on the unlicensed indication of omeprazole oral solution. Please discuss with local paediatrician.

Pack
28 capsule

First choice PPI for children (>1 year and >10kg) who cannot swallow the capsules.

Community first choice PPI for adult patients with swallowing difficulty.

Pack
28 tablet (4 x 7 tablets)
Pack
14 capsule
28 capsule

First choice PPI for children (>1 year and >10kg) who cannot swallow the capsules.

Community first choice PPI for adult patients with swallowing difficulty.

Pack
28 tablet (4 x 7 tablets)
Pack
28 capsule
7 capsule

First choice PPI for children (>1 year and >10kg) who cannot swallow the capsules.

Community first choice PPI for adult patients with swallowing difficulty.

Pack
7 tablet

Unlicensed omeprazole suspensions for paediatric use only.

In some circumstances secondary care may use unlicensed omeprazole suspensions.

Pack
75 ml

Unlicensed omeprazole suspensions for paediatric use only.

In some circumstances secondary care may use unlicensed omeprazole suspensions.

Pack
75 ml

Unlicensed omeprazole oral solution for paediatric use only.

In some circumstances secondary care may use unlicensed omeprazole suspensions.

Pack
1 ml
Pack
5 vial
Pack
14 capsule
28 capsule
56 capsule

Hospital first choice PPI for adult patients with swallowing difficulty.

Pack
28 tablet
Pack
14 capsule
28 capsule
56 capsule
7 capsule

Hospital first choice PPI for adult patients with swallowing difficulty.

Pack
14 tablet
28 tablet
7 tablet
  • On Formulary Preferred
  • On Formulary Second Line
  • On Formulary Third Line
  • Specialist Initiation
  • Secondary Care Only
  • Not Approved for Formulary